Vector Characterization & Validation

CELL AND GENE THERAPY INSIGHTS

April 2019

Vector Characterization & Validation

Download PDF

Editorial

Process validation for recombinant adeno-associated virus vectors in rare diseases: challenges for MAAs

Process validation for recombinant adeno-associated virus vectors in rare diseases: challenges for MAAs

Catherine Cancian

Expert Insight

Challenges and opportunities of machine-guided capsid engineering for gene therapy

Challenges and opportunities of machine-guided capsid engineering for gene therapy

Eric D Kelsic, George M Church

The ongoing evolution and translational potential of novel AAV vectors for human gene therapy

The ongoing evolution and translational potential of novel AAV vectors for human gene therapy

Sabrina Sun, David V Schaffer

Strategies & technologies for the characterization of adeno-associated virus genomes

Strategies & technologies for the characterization of adeno-associated virus genomes

S E Sullivan, E Menesale, S Bergelson et al.

Commentary

Analytical Technology Used in the Latest Development of Gene Therapy Candidates

Analytical Technology Used in the Latest Development of Gene Therapy Candidates

Z Li, Z Wu, T Maekawa et al.

Interview

Preparing an <em>ex vivo</em> gene therapy process for process validation

Preparing an ex vivo gene therapy process for process validation

John Moscariello

Advances and shortfalls in AAV vector characterization

Advances and shortfalls in AAV vector characterization

Christine Le Bec

Preparing to navigate European regulatory requirements for gene therapy process validation

Preparing to navigate European regulatory requirements for gene therapy process validation

Building a LVV characterization and process validation strategy

Building a LVV characterization and process validation strategy

Michael Burnham